[ad_1]
Accepting the recommendation of an advisory committee, the CDC (Center for Disease Control and Prevention) today approved the emergency use of the COVID-19 vaccine developed by Moderna in the United States. The immunizer is the second to receive this type of authorization in the country, the first was from Pfizer / BioNTech, which has already begun to be distributed and applied.
Now, the ACIP (Advisory Committee on Immunization Practices) must define which groups will be added to the vaccination priorities. With the Pfizer immunizer, healthcare professionals and the elderly living in nursing homes were at the top of the list.
Moderna’s vaccine shipments began today moving from storage locations to more than 3,700 healthcare facilities in the U.S., in an effort to distribute the second nationwide approved vaccine and expand the immunization campaign that began. with the vaccine for Pfizer.
The leader of the US coronavirus vaccination program, Moncef Slaoui, said that it was most likely that the first dose of Moderna’s vaccine, which was approved by the FDA (Food and Drug Administration, equivalent to Anvisa ) on Friday (18), will apply tomorrow morning.
“We are looking forward to the vaccine. It will be a little easier to distribute because it does not require temperatures as low as Pfizer’s [para armazená-la]”Slaoui celebrated on CNN.
Some states are choosing Moderna’s vaccine for rural areas because it can be stored for 30 days in standard refrigerators. The Pfizer Immunizer must be shipped and stored at -70ºC and lasts for only five days in refrigerators with standard temperatures.
The US government plans to administer 5.9 million doses of Moderna and 2 million doses of Pfizer next week. But the ambitious goal of giving the first of two necessary doses to 20 million people by the end of the year could be extended until the first week of January, said Army General Gustave Perna, who coordinates the dose distribution operation.
The launch of Moderna’s vaccine delivery will significantly increase the availability of the vaccine at a time when deaths in the U.S. from covid-19 have reached more than 316,000 in the 11 months since the first documented case in the country.
Vaccines in Brazil
Four possible vaccines against covid-19 are being tested in Brazil: the University of Oxford vaccine, developed in partnership with AstraZeneca; CoronaVac, from the Chinese laboratory Sinovac with the Butantan Institute; the Pfizer vaccine with BioNTech; and the vaccine from the Belgian laboratory Janssen-Cilag.
All are in the final phase of clinical trials, the so-called phase 3, and have already presented some results of the entire study process to Anvisa (National Health Surveillance Agency), responsible for the regulation of vaccines and drugs in Brazil.
The clinical study of a vaccine is divided into some stages, ranging from the exploratory or laboratory phase, when the components are still being evaluated for a better vaccine formulation; go through the preclinical phase, when testing on animals; finally reaching the clinical stage. This, in turn, is subdivided into three other stages: phases 1, 2 and 3.
(With Reuters)
